U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 112

1.
Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib
Yuki Sato, Yoshiharu Sato, Kei Irie, Shigeki Nanjo, Shigeo Hara, Satoru Fujiwara, Keisuke Tomii
Thorac Cancer. 2024 Aug; 15(23): 1772–1775. Published online 2024 Jun 24. doi: 10.1111/1759-7714.15395
PMCID:
PMC11320077
AbstractArticlePDF–2.8M
2.
Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy
Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah-Planchon, Alexandra Saint-Charles, Angela Bellini, Jaydutt Bhalshankar, Gaelle Pierron, Valérie Combaret, Valéry Attignon, Nicolas André, Nadège Corradini, Benoit Dumont, Ludovic Mansuy, Camille Khanfar, Sebastien Klein, Claire Briandet, Dominique Plantaz, Frederic Millot, Sandrine Thouvenin, Isabelle Aerts, Lee Aymar Ndounga-Diakou, Salim Laghouati, Samuel Abbou, Nina Jehanno, Hubert Tissot, Shufang Renault, Sylvain Baulande, Virginie Raynal, Laurence Bozec, Ivan Bieche, Olivier Delattre, Pablo Berlanga, Gudrun Schleiermacher
Clin Cancer Res. 2024 Aug 1; 30(15): 3316–3328. Published online 2024 May 24. doi: 10.1158/1078-0432.CCR-24-0753
PMCID:
PMC11292203
AbstractArticlePDF–3.3M
3.
IC Regimen: Delaying Resistance to Lorlatinib in ALK Driven Cancers by Adding Repurposed Itraconazole and Cilostazol
Richard E. Kast
Cells. 2024 Jul; 13(14): 1175. Published online 2024 Jul 10. doi: 10.3390/cells13141175
PMCID:
PMC11274432
AbstractArticlePDF–1.5M
4.
Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC
Konstantinos Arnaoutakis, Yin Wan, Jennifer Elliott, Matt Young, Yu Yin, Konstantinos Leventakos, Huamao M. Lin, Anastasios Dimou
Adv Ther. 2024; 41(8): 3217–3231. Published online 2024 Jun 25. doi: 10.1007/s12325-024-02899-6
PMCID:
PMC11263478
AbstractArticlePDF–1.2M
5.
Anaplastic Lymphoma Kinase signaling stabilizes SLC3A2 expression via MARCH11 to promote neuroblastoma cell growth
Wei-Yun Lai, Tzu-Po Chuang, Marcus Borenäs, Dan E. Lind, Bengt Hallberg, Ruth H. Palmer
Cell Death Differ. 2024 Jul; 31(7): 910–923. Published online 2024 Jun 10. doi: 10.1038/s41418-024-01319-0
PMCID:
PMC11239919
AbstractArticlePDF–2.0M
6.
LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion
Shunta Mori, Hiroki Izumi, Mitsugu Araki, Jie Liu, Yu Tanaka, Yosuke Kagawa, Yukari Sagae, Biao Ma, Yuta Isaka, Yoko Sasakura, Shogo Kumagai, Yuta Sakae, Kosuke Tanaka, Yuji Shibata, Hibiki Udagawa, Shingo Matsumoto, Kiyotaka Yoh, Yasushi Okuno, Koichi Goto, Susumu S. Kobayashi
Commun Biol. 2024; 7: 412. Published online 2024 Apr 4. doi: 10.1038/s42003-024-06116-6
PMCID:
PMC10995188
AbstractArticlePDF–1.1M
7.
Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase‐positive non‐small‐cell lung cancer
Yuki Shimomura, Kenji Sawa, Takumi Imai, Yasutaka Ihara, Hisako Yoshida, Ayumi Shintani
Cancer Sci. 2024 Mar; 115(3): 926–936. Published online 2023 Dec 27. doi: 10.1111/cas.16056
PMCID:
PMC10920989
AbstractArticlePDF–2.1M
8.
CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles
Marc Terrones, Christophe Deben, Felicia Rodrigues-Fortes, Anne Schepers, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer
J Transl Med. 2024; 22: 234. Published online 2024 Mar 3. doi: 10.1186/s12967-024-04988-0
PMCID:
PMC10910754
AbstractArticlePDF–5.1M
9.
Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
Wenjie Liu, Gengwei Huo, Peng Chen
Front Public Health. 2024; 12: 1213318. Published online 2024 Feb 15. doi: 10.3389/fpubh.2024.1213318
PMCID:
PMC10906082
AbstractArticlePDF–710K
10.
Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase (ALK)‐positive lung cancer and multiple brain metastases
Yosuke Murakami, Yosuke Kawashima, Shinji Chiba, Shuichiro Hara, Yusuke Yamazaki, Tsuyoshi Doman, Shin Saito, Tetsuo Odaka, Takahiro Ogasawara, Hisashi Shimizu, Jun Sugisaka, Tomoiki Aiba, Yukihiro Toi, Shinsuke Yamanda, Yuichiro Kimura, Shunichi Sugawara
Cancer Rep (Hoboken) 2024 Feb; 7(2): e1981. Published online 2024 Jan 11. doi: 10.1002/cnr2.1981
PMCID:
PMC10864716
AbstractArticlePDF–2.3M
11.
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis
Mingye Zhao, Taihang Shao, Hanqiao Shao, Caicun Zhou, Wenxi Tang
BMC Cancer. 2024; 24: 186. Published online 2024 Feb 8. doi: 10.1186/s12885-024-11916-4
PMCID:
PMC10851546
AbstractArticlePDF–3.7M
12.
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
Joseph Chen, Alessandra Bearz, Dong-Wan Kim, Hirva Mamdani, Jessica Bauman, Rita Chiari, Sai-Hong Ignatius Ou, Benjamin J. Solomon, Ross A. Soo, Enriqueta Felip, Alice T. Shaw, Holger Thurm, Jill S. Clancy, Kimberly Lee, Melissa O’Gorman, Cherie Tanski, Yazdi K. Pithavala
Clin Pharmacokinet. 2024; 63(2): 171–182. Published online 2023 Dec 11. doi: 10.1007/s40262-023-01309-4
PMCID:
PMC10847213
AbstractArticlePDF–1.0M
13.
SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma
Ivette Valencia-Sama, Lynn Kee, Gabriella Christopher, Michael Ohh, Mehdi Layeghifard, Adam Shlien, Madeline N. Hayes, Meredith S. Irwin
Cancer Res Commun. 2023 Dec; 3(12): 2608–2622. Published online 2023 Dec 27. doi: 10.1158/2767-9764.CRC-23-0234
PMCID:
PMC10752212
AbstractArticlePDF–10M
14.
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
Cesare Gridelli, Marcello Tiseo, Diego Luigi Cortinovis, Maria Rita Migliorino, Vito Barbieri, Paolo Bironzo, Alessandra Bearz, Ilaria Attili, Filippo de Marinis
Curr Oncol. 2023 Nov; 30(11): 10033–10042. Published online 2023 Nov 20. doi: 10.3390/curroncol30110729
PMCID:
PMC10670405
AbstractArticlePDF–265K
15.
Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report
Jie Li, Junwei Liu, Guqin Zhang, Weidong Hu, Xianguo Wang, Jun Liu
Am J Case Rep. 2023; 24: e942150-1–e942150-5. Published online 2023 Nov 7. doi: 10.12659/AJCR.942150
PMCID:
PMC10642716
AbstractArticlePDF–2.0M
16.
Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults
Jessica Stiefel, Brian H. Kushner, Stephen S. Roberts, Fiorella Iglesias-Cardenas, Kim Kramer, Shakeel Modak
JCO Precis Oncol. 2023; 7: e2300138. Published online 2023 Aug 10. doi: 10.1200/PO.23.00138
PMCID:
PMC10581627
AbstractArticlePDF–1.1M
17.
The Exploration of Chirality for Improved Druggability within the Human Kinome
Debasmita Saha, Anupreet Kharbanda, Wei Yan, Naga Rajiv Lakkaniga, Brendan Frett, Hong-Yu Li
J Med Chem. Author manuscript; available in PMC 2023 Sep 28.
Published in final edited form as: J Med Chem. 2020 Jan 23; 63(2): 441–469. Published online 2019 Oct 9. doi: 10.1021/acs.jmedchem.9b00640
PMCID:
PMC10536157
AbstractArticlePDF–5.0M
18.
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Geoffrey Liu, Vincent K. Lam
Adv Ther. 2023; 40(10): 4117–4126. Published online 2023 Aug 12. doi: 10.1007/s12325-023-02606-x
PMCID:
PMC10499938
AbstractArticlePDF–244K
19.
A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
Bei Zheng, Hong Jiang, Wenjuan Yang, Ying Li, Bingqing Liang, Jun Zhu, Nanmei Chen, Miao Chen, Meiling Zhang
Cancer Med. 2023 Aug; 12(15): 15983–15997. Published online 2023 Jun 19. doi: 10.1002/cam4.6241
PMCID:
PMC10469807
AbstractArticlePDF–3.8M
20.
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
Martin Rupp, Fiorella Fanton-Aita, Stephanie Snow, Paul Wheatley-Price, Barbara Melosky, Rosalyn A. Juergens, Quincy Chu, Normand Blais, Shantanu Banerji, Ryan Ng, Shoghag Khoudigian, Arushi Sharma, Phu Vinh On, Geoffrey Liu
Curr Oncol. 2023 Jul; 30(7): 6559–6574. Published online 2023 Jul 8. doi: 10.3390/curroncol30070481
PMCID:
PMC10377946
AbstractArticlePDF–1.7M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed Central (PMC)
Support Center